دورية أكاديمية
Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study.
| العنوان: | Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study. |
|---|---|
| المؤلفون: | Hurwitz HI; Division of Hematology and Oncology, Duke University Medical Center, Durham, NC, USA. Electronic address: herbert.hurwitz@duke.edu., Bekaii-Saab TS; Department of Internal Medicine, The Ohio State University Medical Center, Columbus, OH, USA., Bendell JC; Department of Gastrointestinal Oncology, Sarah Cannon Research Institute, Nashville, TN, USA., Cohn AL; Department of Medical Oncology, Rocky Mountain Cancer Center, Denver, CO, USA., Kozloff M; Department of Hematology & Oncology, Ingalls Hospital and University of Chicago, Harvey, IL, USA., Roach N; Patient Advocacy, FightColorectalCancer.org, Alexandria, VA, USA., Mun Y; U.S. Medical Affairs, Genentech, Inc., South San Francisco, CA, USA., Fish S; U.S. Medical Affairs, Genentech, Inc., South San Francisco, CA, USA., Flick ED; U.S. Medical Affairs, Genentech, Inc., South San Francisco, CA, USA., Grothey A; Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA. |
| مؤلفون مشاركون: | ARIES Study Investigators |
| المصدر: | Clinical oncology (Royal College of Radiologists (Great Britain)) [Clin Oncol (R Coll Radiol)] 2014 Jun; Vol. 26 (6), pp. 323-32. Date of Electronic Publication: 2014 Mar 28. |
| نوع المنشور: | Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: W.B. Saunders Country of Publication: England NLM ID: 9002902 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1433-2981 (Electronic) Linking ISSN: 09366555 NLM ISO Abbreviation: Clin Oncol (R Coll Radiol) Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2003- : London : W.B. Saunders Original Publication: [London, UK] : Springer International, [c1989- |
| مواضيع طبية MeSH: | Angiogenesis Inhibitors/*therapeutic use , Antibodies, Monoclonal, Humanized/*therapeutic use , Colorectal Neoplasms/*drug therapy, Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bevacizumab ; Cohort Studies ; Colorectal Neoplasms/mortality ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Registries ; Young Adult |
| مستخلص: | Aims: The Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study (OCS) was designed to prospectively examine outcomes associated with bevacizumab-containing treatment for metastatic colorectal cancer (mCRC) in a community-based setting, where patient populations are less restricted than those in randomised trials. Materials and Methods: Patients with mCRC who were eligible for bevacizumab in combination with chemotherapy in first- or second-line treatment were enrolled from November 2006 to September 2008. There were no protocol-specified treatment regimens; the dose and schedule of bevacizumab and chemotherapy were at the treating physician's discretion. The objectives in the ARIES OCS included analyses of progression-free survival (PFS), overall survival, treatment patterns and safety in each of the first- and second-line treatment cohorts. Results: ARIES enrolled 1550 patients with mCRC receiving first-line therapy with bevacizumab. The median follow-up time was 20.6 months. The median PFS in this cohort was 10.2 months (95% confidence interval 9.8-10.6) and the median overall survival was 23.2 months (95% confidence interval 21.2-24.8). In a separate cohort of 482 patients with second-line mCRC, the median follow-up time was 16.9 months, the median PFS and overall survival from the start of second-line treatment to the end of follow-up was 7.9 months (95% confidence interval 7.2-8.3) and 17.8 months (95% confidence interval 16.5-20.7), respectively. Incidences of known bevacizumab-associated adverse events in ARIES were generally consistent with those previously reported in OCSs and randomised trials. Conclusion: Results from the prospective ARIES OCS add further evidence to support the effectiveness and safety of bevacizumab when added to first- and second-line treatment regimens for patients with mCRC in community treatment settings. (Copyright © 2014 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Bevacizumab; colorectal cancer; observational cohort study |
| المشرفين على المادة: | 0 (Angiogenesis Inhibitors) 0 (Antibodies, Monoclonal, Humanized) 2S9ZZM9Q9V (Bevacizumab) |
| تواريخ الأحداث: | Date Created: 20140402 Date Completed: 20150821 Latest Revision: 20220316 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1016/j.clon.2014.03.001 |
| PMID: | 24686090 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1433-2981 |
|---|---|
| DOI: | 10.1016/j.clon.2014.03.001 |